United States Patent 8,178,563 (US8178563): scope, claim coverage, and patent landscape analysis of hedgehog-pathway inhibitors
What is US 8,178,563 protecting under its Formula I claims?
US 8,178,563 is a small-molecule patent focused on compounds defined by a broad “Formula I” scaffold, with substantial variability in ring substitution patterns and appended solubilizing/heterocycle groups. Claim scope is primarily chemical (Markush-style genus) and extends into downstream biological method claims for hedgehog-pathway inhibition in cells and therapeutic targeting in specific cancers.
How the Formula I genus is structured
Claim 1 defines “a compound of Formula I” plus pharmaceutically acceptable salts or stereoisomers. Coverage is governed by substituent variables R1 through R12 (as expressed in the claim), plus:
- A constraint that R6 and R7 are not both hydrogen
- Variable R9 that selects one of several functional classes (sulfonyl, ether, amide/carbonyl, or N-substituted amine motif types), with R11 constrained to a list of cyclic tertiary amine/heterocycle groups (thiomorpholino, sulfonomorpholino, morpholino, azepane, oxazepane, piperidinyl, tetrahydro-pyranyl, piperazinyl, pyrrolidinyl, diazepan-1-yl, etc.)
- Optional substitution on R11-bearing substituents (1 to 3 radicals) for some R11 types, including benzyl and substituted benzyl patterns
Dominant “design knobs” in Claim 1
The claim’s breadth comes from independent selection at multiple positions:
1) Aromatic/biphenyl core substitution (R2–R8, R6/R7 constraint)
- R2 and R5: H / cyano / halo / alkyl / alkoxy / dimethylamino variants
- R3 and R4: H / halo / cyano / alkyl / alkoxy variants
- R6 and R7: H or halo/fluoro or alkyl/alkoxy variants, but not simultaneously H
- R8: another halo/alkyl/alkoxy selector
This supports many regio-isomers and electronic variants on the biaryl system.
2) Linker and polarity module (R9 and R11)
- R9 selects among:
- —S(O)2R11 (sulfonamide/sulfone-like functionality)
- —OR11 (ether linkage)
- —C(O)R11 (carbonyl linkage)
- —NR12aR12b (tertiary/secondary amide-like or amine substituent class depending on R12 selections)
- —R11 (direct substitution class)
- R11 is limited to a defined set of morpholine-family or saturated heterocycle amines (plus others listed).
- R12a and R12b are restricted (notably including isobutyl and hydroxyethyl in the provided claim text), tying the N-substituted class to specific solubilizing groups.
3) Optional substitution on the R11-associated aromatic/binding group
The claim allows additional substituents (1 to 3) on the substituent attached to R9 where benzyl is used (and includes examples with diazepane- or piperazine-containing benzyl motifs). That drives meaningful coverage of “analog” chemical matter, not just a single fixed lead.
Featured list style answer (scope in plain terms)
Claim 1 covers a genus of biaryl carboxamide-type hedgehog-pathway inhibitors (and related functional embodiments) where:
- Biaryl substituents vary at multiple positions (cyano/halo/alkyl/alkoxy/dimethylamino allowed)
- A cyclic amine (morpholine/azepane/oxazepane/piperazine/piperidine/pyrrolidine/diazepane variants) is incorporated via R11 and linked through an ether/sulfone/amide/carbonyl selector (R9)
- One stereochemical option is expressly supported (stereoisomers)
- A non-trivial substitution constraint exists: R6 and R7 cannot both be H
Which specific compounds are explicitly enumerated in dependent Claim 5?
Claim 5 contains a long “selected from” list, enumerating numerous concrete chemical entities falling within the Claim 1 genus.
What the enumerated set reveals about the invention’s core
Across the enumerated compounds, the repeated motifs are:
- A biphenyl system with:
- cyano and/or trifluoromethoxy substituents
- additional methyl/halo/alkoxy variants across the rings
- A carboxamide functionality (explicitly “-carboxamide” in many names)
- A pendant heterocycle amine group (notably morpholine / dimethylmorpholine / morpholino, plus azepane, oxazepane, piperazine, piperidine, tetrahydro-pyran-4-yloxy type, and related saturated heterocycles)
- Stereo-defined exemplars using (2R,6S)-2,6-dimethylmorpholino and (R)/(S) labeling for the overall stereocenter(s)
Practical claim-coverage implication
Enumerated compounds in Claim 5:
- Anchor the patent to specific representative embodiments the applicant likely prepared and tested
- Reduce indefiniteness risk for the genus (in examination and later litigation, enumerations can support enablement and written description arguments tied to the exemplars)
- Provide strong infringement “targets” for generic entrants evaluating design-around compounds that may still land inside Formula I or its functional classes
Do the dependent claims narrow the chemistry, or expand it?
They narrow in some dimensions, but they preserve large breadth.
Claim 2: narrowed R6/R7 and R8 sets
Claim 2 constrains R6 and R7 to a smaller list (H, methyl, chloro, fluoro, bromo, trifluoromethyl, methoxy) with the same “not both H” rule. R8 is restricted to H/fluoro/chloro/methyl/trifluoromethyl.
Effect: This is still broad (halogens, trifluoromethyl, methoxy, methyl), but it excludes many alkyl/alkoxy lengths and other substituted patterns.
Claim 3: additional narrowing by listing explicit acceptable R1–R5 and R3/R4 sets
Claim 3 narrows allowed substituents at key positions:
- R1 limited to cyano and various simple alkyls including t-butyl, iPr, iBu, alkoxy variations, dimethylamino, trifluoromethyl, trifluoromethoxy, and piperazinyl (with up to two methyl substituents)
- R2 and R5 limited to H/halo/cyano/methyl/trifluoromethyl/isopropyloxy/methoxy/ethoxy/trifluoromethoxy/dimethylamino
- R3 and R4 limited to H/halo/methyl/methoxy/cyano
Effect: Again, still large, but it excludes many “longer” halo-alkyl/halo-alkoxy and many substituent classes included in Claim 1.
Claim 4: fixes R8 = hydrogen
Claim 4 further narrows R8 to H, eliminating R8 variants.
Claims 10–12: additional specific compound claims
Claims 10–12 focus on a specific named compound:
“N-(6-((2R,6S)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide” (and related stereochemical/descriptor variants).
Effect: These are narrower, but provide clean, single-entity claim targets for enforcement and licensing. If any marketed or development compound matches this exact scaffold, it is a direct infringement hook independent of broader genus interpretation.
How far do method claims extend beyond chemistry?
The patent includes hedgehog-pathway and cancer-relevant functional method coverage.
Claim 6: hedgehog-pathway inhibition in a cell
Claim 6 covers “a method of inhibiting the hedgehog pathway in a cell” by contacting the cell with a compound of Claim 1.
Scope: Functional, dependent on use of Claim 1 compounds. This matters if an accused product uses a covered compound even without matching exact therapeutic indications.
Claim 7: phenotype-of-function dependent cells
Claim 7 narrows to cells with phenotypes such as:
- Ptc loss-of-function
- hedgehog gain-of-function
- smoothened gain-of-function
- Gli gain-of-function
Scope: Ties to canonical hedgehog pathway biology, likely matching assay systems used during development.
Claim 8: therapeutic application in animals with specified cancers
Claim 8 specifies administration to an animal with therapeutic application selected from:
- pancreatic cancer
- prostate cancer
- medulloblastoma
- basal cell carcinoma
- small-cell lung cancer
Claim 9: unwanted proliferation in cells for the same cancer list
Claim 9 covers “inhibiting unwanted proliferation of a cell” for cell selection from the same cancer types.
Scope implication: If any clinical program uses covered compounds in these indications, the method claims can create additional infringement vectors beyond pure composition claims, including for activities performed in R&D and downstream preclinical work.
What does US 8,178,563 imply for hedgehog-targeted small-molecule competitive strategy?
The claim set indicates a therapeutic class positioning around hedgehog pathway inhibition with a distinctive biaryl carboxamide core and saturated heterocycle solubilization groups.
Chemical design space protected by the patent
Protected design space includes:
- Biaryl substitution patterns with cyano/halo/alkoxy/dimethylamino motifs
- Ether/sulfone/carbonyl/amine-linkage to heterocycle amines (R11)
- Specific stereochemical configurations for some exemplars
- A broad selection of “morpholino-family” and related amine rings
Where design-arounds are likely to fail
Given the broad functional selection at R9 and the large list of allowed R11 groups, simple changes such as:
- swapping one halogen for another within allowed sets
- altering alkyl vs alkoxy within Claim 1’s constraints
- moving between ether vs sulfone vs carbonyl linkages that are still within the R9 options
can still land inside Claim 1 (and potentially Claims 2–3 depending on the substitution lists).
Where design-arounds can succeed (typology)
Design-around success typically requires moving outside:
- the allowed R9 linkage class set, or
- the R11 heterocycle list, or
- the restricted substitution combinations at the biaryl positions
- or removing the R6/R7 not-both-H pattern (if the target needs both H, depending on the accused structure)
Because Claim 1 uses a Markush genus, the litigation hinge often becomes whether an accused compound fits the selected alternatives literally (or under doctrine of equivalents, depending on claim construction and prosecution history). The dependent claims’ narrower lists offer additional fallback positions for the patentee.
What is the infringement and licensing posture suggested by the claim structure?
The patent has a layered enforcement strategy:
-
Composition genus claim (Claim 1)
Broad chemical coverage for many analogs.
-
Narrowed genus subsets (Claims 2–4)
Provide fallback if Claim 1 is construed narrowly (claim interpretation risk management).
-
Enumerated exemplar list (Claim 5)
Provides named infringement targets within the genus.
-
Single-compound claims (Claims 10–12)
Provide cleaner, lower-interpretation disputes for key exemplars.
-
Method claims (Claims 6–9)
Enables additional leverage tied to hedgehog pathway functional activity and specified cancer indications.
This structure is typical of patents intended to survive claim construction fights and still reach real-world development compounds.
What patent landscape questions are determinable from Claim text alone?
Only limited answers can be produced without external bibliographic and prosecution data (priority dates, prosecution history, family members, assignees, legal status, and which applicant’s compound corresponds to the enumerated list). The claim text alone does not provide:
- Priority/filing dates needed for expiration timelines
- Other family patents in the same lineage
- Orange Book listings or FDA NDA/ANDA mappings
- Litigation/settlement records
- Assignment data tied to current enforcement entities
Because those require external records, no definitive landscape assertions are made here.
Key Takeaways
- US 8,178,563 Claim 1 is a broad Markush genus covering biaryl carboxamide (and related functional variants) hedgehog-pathway inhibitors with extensive substitution latitude across R1–R8 and a constrained linkage and heterocycle selection through R9/R11.
- Dependent claims (2–4) narrow allowable substituent lists and fix specific positions (notably R8), functioning as fallback claim sets.
- Claim 5 enumerates many specific chemical entities, providing concrete infringement targets and supporting written description/enablement around the genus.
- Method claims (6–9) extend protection to hedgehog pathway inhibition in hedgehog-relevant cell phenotypes and to therapeutic administration and anti-proliferation in multiple cancer indications (pancreatic, prostate, medulloblastoma, basal cell carcinoma, small-cell lung cancer).
- The enforcement profile is layered: genus composition, narrower composition subsets, explicit exemplar list, specific compound claims, and functional method claims tied to hedgehog biology and cancer indications.
FAQs
-
Does US 8,178,563 require a specific hedgehog pathway genotype (Ptc/Smo/Gli) to infringe?
Only Claim 7 requires those phenotypes; Claim 6 covers hedgehog pathway inhibition in cells generally when contacting with Claim 1 compounds.
-
If an accused compound swaps a halogen or alkyl for another within R1–R8 lists, does it still fall within Claim 1?
It can, because Claim 1 allows broad sets of cyano, halo, alkyl, alkoxy, and dimethylamino substitutions at multiple positions.
-
Are salts and stereoisomers covered separately from the base compound?
Yes. Claim 1 expressly includes pharmaceutically acceptable salts and stereoisomers.
-
What is the practical role of Claims 10–12 versus the broader Formula I claims?
They provide single-compound coverage for specific named stereostructured exemplars, lowering interpretive friction if an accused product matches those exemplars.
-
Can method-of-use claims be implicated even if a product is not developed for one of the listed cancers?
Claim 8/9 require therapeutic application or unwanted proliferation in the listed cancer contexts; if the accused use falls outside those contexts, those specific method claims are harder to apply, though Claim 6 may still be implicated for hedgehog pathway inhibition depending on the factual use.
References
No external sources were cited because the prompt provided only the claim text, not bibliographic records, legal status, assignees, filing dates, or FDA/Orange Book linkages.
